Mutlay Sayan, MD

Faculty Update! 📣 Additional thought leaders have joined the faculty lineup for #WorldGU26! The roster is live on our website, featuring our conference chairs @CaPsurvivorship & @Daniel_J_George and 80+ national experts in genitourinary oncology: ow.ly/ypzK50YzYcl The 2-day CE-accredited conference will be back in Nashville, TN, on December 3-5, 2026. Save the date and stay tuned for registration launching soon! Who are you most excited to hear from? @aaparicioMD @tingbao2011 @PBarataMD @katy_beckermann @mishabeltran @jackiebrown_MD @AlanBryce9 @drjefstathiou @MarkTFlemingMD1 @BGarmezy @OncHahn @MRHarrisonMD @EHeath4100 @EJonasch @MonikaJoshimd @jonathan_leeman @PavlosMsaouel @maughanonc @BradMcG04 @CParkMD @drphil_urology @EdwinPosadasMD @charlesryanmd @MutlaySayan @Scarps_kristen @cnsternberg @sonpavde @sandysrimd @alantanmd @DrKarineTawagi @drulkav @jeffyoriomd @bilenma @TDorffOnc @NaomiHaas5 @MikeLattanzi @MoningiShalini @ashleyrossmdphd @bsomer

Had an absolute blast hosting the inimitable @DrPaulNguyen at @RadOncTMC. World-class mind, zero airs 😄 Residents brought their A-game with their presentations. Inspiring, energizing, charming and a whole lot of fun. Had our residents thinking, and smiling. 🙂 Brilliant!

A fantastic meeting filled with collaboration and new ideas. Can’t wait for next year! 🙌 @GUconference

Congratulations!

Join us in celebrating our 2026 Award Recipients. 🎉 Gold Medalists: @hedvighricak @DrDMonticciolo Honorary Fellows: @banu_atalar @Kriklund Bien Soo Tan, MD We look forward to recognizing these honorees during #ACR2026. Learn more: bit.ly/4ohTfIg

This year's @ASTRO_org is a big meeting for GU trials and science! I'm looking forward to hearing the results of many important GU trials such as: 🔬 Monday's 1:30 Plenary session - NRG GU005, BART 🔬 Sunday's 1:00 Clinical trials session - LUNAR, NRG GU006, NRG/RTOG 0924 🔬 Plus all of the Educational and Science sessions! What are you looking forward to most this year? @RonaldChenMD @jmmrad @DrHowardSandler @SameerKeoleMD @NehaVapiwala @Doug_Radonc @ChelseaPinnix @DrChrisCorso @CurtilandD @DrMalikaSiker @catherynyashar @IBCradiation @A_CT_SimMDJD @ZacharyBWhiteII @EmilyHollis @Ggreen1986 @MorganSLevy @Hysr_Ly @NataliyaMedPhys @MustafaBasree @RadOncDoc_Niema @TheMedNet @l_ballas @VedangMurthy @DrSpratticus @vedangmurthy @AmarUKishan @NRGonc @DrPaulNguyen #ASTRO25 #RadiationOncology #CancerResearch

👏 Celebrating #WorldGU25 Honored to take the stage at the World Conference on Genitourinary Cancers recently in Nashville! It was an incredible setting at the Country Music Hall of Fame and Museum and a privilege to contribute alongside so many leaders in the field. A highlight for me was hearing Olympian high jumper Chaunté Lowe share her inspiring story of beating cancer, a reminder of the resilience and dedication that drives us all. Big congratulations to Alicia Morgans, M.D., MPH and Dan George, M.D. and the entire IDEOlogy Health team for hosting such a successful meeting. And thanks to the dynamic Mark Pomerantz for hosting GU Pardy and congratulations to Team Bladder who won the World GU-Pardy finale, securing a $2,500 donation to BCAN in support of bladder cancer research and advocacy! The program was highly educational and insightful. It was the perfect balance of learning, collaboration, fun, and community. I'm already looking forward to next year! #WorldGU25 #Oncology #CancerResearch #MedicalEducation #Urology #OncologyCommunity @countrymusichof @cchauntelowe @CaPsurvivorship @Daniel_J_George @michaelabern @DanBarocas @katy_beckermann @bergsa83 @bilenma @BraunMDPhD @UroCancerMD @jackiebrown_MD @mkbupathi @DrCaliff_FDA @DrDarrenFeldman @MarkTFlemingMD1 @Bgarmezy @RajanTGuptaMD @HHammersMD @MRHarrisonMD @EHeath4100 @KHoffmanMD @HJacene @EJonasch @MonikaJoshimd @MikeLattanzi @jonathan_leeman @LoebStacy @Dr_RaviMadan @maughanonc @MattMilowsky @CParkMD @DrJohnGPhillip1 @drphil_urology @ERPlimackMD @EdwinPosadasMD @brian_rini @ashleyrossmdphd @MutlaySayan @MikeSchweizerMD @KidneyCancerDoc @bsomer @DrVaishampayan @jeffyoriomd @Alantanmd @DrKarineTawagi @charlesryanmd @IDEOlogyHealth @oncodaily @BladderCancerUS

What happens when GU experts tackle the toughest real-world cases together? Next at #WorldGU25, @bilenma (Chair), @MRHarrisonMD, @Scarps_kristen, Elizabeth Kessler, MD, @MutlaySayan & @JohnPhillipsMD lead an unmissable session: Case-Based Therapeutic Interventions in GU Cancers – Maximizing MDT Resources. hubs.la/Q03D_nRN0 #guoncology

Excellent editorial on the DADSPORT meta-analysis: sciencedirect.com/science/articl…

Happy first day of #HROP residency to our beaming first-year residents!!

Ağustos’ta Nashville’de düzenlenecek #WorldGU25 konferansında konuşmacı olarak yer almaktan onur duyuyorum. Sunumumda prostat kanserinde hassas tedavi yaklaşımlarını nasıl uygulayabileceğimizi ele alacağım—sizleri de aramızda görmekten mutluluk duyarım! 🔗worldguconference.com

Honored to be speaking at #WorldGU25 this August in Nashville. I’ll be talking about how we can apply precision management in prostate cancer care—hope you’ll join us! 🔗 worldguconference.com @GUconference @HarvardRadOnc

Congratulations to our HROP Class of 2025 - excited to see you flourish in the next step of your careers as attendings, physician scientists, and leaders in medicine, you are all wonderful! 🥲

1️⃣ Elective Regional Nodal Irradiation in Prostate Cancer 👥 With @DrSrinivas_C, @MutlaySayan & @a_dalpra 🎯 We cover rationale, patient selection & key trials shaping WPRT in high-risk, SBRT and post op settings. Read 📖 doi.org/10.1016/j.semr…

During residency, when modems crackled and PubMed barely loaded, I relied on Sem in Rad Oncol for the latest info. Contributing 2 articles to its latest issue on #prostatecancer is a full-circle moment. 🙏🏼 What @sophia_kamran and @CZamboglou have put together is a masterpiece.

✨Insightful (and must-read) editorial by @MutlaySayan & @DrPaulNguyen in @EUplatinum : ➡️As ADT shows modest OS benefit post-prostatectomy, the future lies in precision, leveraging PSMA PET, genomic classifiers, and AI to guide who really needs treatment intensification. @OncoAlert @APCCC_Lugano @DrYukselUrun @PCFnews #ProstateCancer #Cancer #Oncology #MedTwitter Link: europeanurology.com/article/S0302-…

🗣️Prostate Oral Abstract #ASCO25 👉Abst5000: Dr #TedDeWeese presenting #CAN2409+prodrug +EBRT +/-ADT in Int/High Risk PCa #CAN2409 is a replication-defective adenovirus 🦠HSV-tk gene 🧬 w/ prodrug promoting immunogenic cell death ☠️ and immunize 💉against tumor antigens for long-term tumor control. n = 745 Int Risk = 85% High Risk = 15% median follow up 50.3mo Randomization 2:1 💉 #CAN2409 + prodrug -> EBRT +/- ADT 💉 Placebo + prodrug -> EBRT +/- ADT ✅ mDFS: NR vs 86.1 mo (HR 0.7, 0.52 to 0.94) ✅ PCa-PFS: (HR 0.62; 0.44 to 0.87) ✅ PSA nadir: 67.1% vs 58.6% (p=0.0164) ✅ 2yr Path CR: 80.4% vs. 63.6% (p=0.0015 ⚠️ SAE: 5.8% vs. 7.3% ⚠️ TRSAEs 1.7% vs. 2.2% ⚠️ Chills 33.4% vs. 8.6% ⚠️ Flu 30.5% vs. 13.8% ⚠️ Fever 25.1% vs. 3.9% 🔑 KEY TAKE AWAYS - #CAN2409 significantly improved DFS and PCa-DFS r when added to SoC EBRT+/- ADT for localized PCa - #CAN2409 a/w favorable AE profile SAEs ~5% and common AEs G1-2 fevers/malaise. 🤯First potentially new therapy for patients with Int-High Risk PrCa in over 20 years! 🔥 Evidence from additional tumors that #CAN2409 heats up TME to facilitate immune response! 👥@DrChoueiri @neerajaiims @Silke_Gillessen @APCCC_Lugano @Prof_Nick_James @CParkMD @ChrisSweens1 @AtishChoudhury @TDorffOnc @xiaoweimd @angela_jia_ @pearldaily @BourlonMaite @bavilima @MutlaySayan @nataliagandur @OncoAlert @OncBrothers @urotoday

🗣️Prostate Oral Abstract #ASCO25 👉Abst5001: Dr @Prof_Nick_James presenting #MMAI for benefit from ARPI in high risk M0 PCa #STAMPEDE 🤖Multimodal AI #MMAI algorithm (@arteraAI Prostate Test v1.2) High-risk M0 STAMPEDE (w/ H&E images& clinical data) >2/3 Risk Factors (T3-4, Gleason 8-10, PSA >20) 💊SOC+ARPI (N=555) 💊SOC (N=781) median follow up 6 years Continuous MMAI scores a/w: ✅ PCSM (1.65; 1.43-1.90, p<0.001) ✅ MFS (1.42; 1.29-1.56, p<0.001) ✅ DM (1.54; 1.36-1.74, p<0.001). 📊Optimal cut-point was identified via grid search to maximize ARPI benefit across biomarker pos & neg ✅Biomkr POS: PCSM (0.42; 0.24-0.74, p=0.003) ✅Biomkr NEG: PCSM (0.85; 0.56-1.29, p=0.45) ✅Biomkr POS: 5Y-PCSM = 9% ARPI vs 17% SOC ✅Biomkr NEG: 5Y-PCSM = 4% ARPI vs 7% SOC 🔑 KEY TAKE AWAYS - #MMAI algorithm can identify high-risk M0 PCa pts who most likely to benefit from the addition of ARPI. - #MMAI could optimize Tx intensification w/ ARPI (biomkr POS) & Tx de-intensification in (biomkr NEG) 👥 @DrChoueiri @neerajaiims @Silke_Gillessen @APCCC_Lugano @Prof_Nick_James @DrSpratticus @BourlonMaite @pearldaily @AtishChoudhury @MutlaySayan @drenriquegrande @bavilima @DRBakaloudiMD @nataliagandur @OncoAlert @OncBrothers @urotoday @PCFnews

.@HarvardRadOnc takes @ESTRO_RT 🇦🇹: Congrats to @MinaBakhtiar presenting on automated pre-treatment tumor burden imaging to predict ctDNA in #HPV oropharynx cancer & @morayouknow on #AI large language model cancer treatment information differences based on bilingual prompting

UROK 2025 has just started! The Bi-annual meeting of Turkish Society for Radiation Oncology has made a great start with our international guests. Stay tuned… @SbrtSean @SimonLo21054188 @MutlaySayan